23 janvier 2025
Genethon and Eukarÿs announce strategic partnership to develop breakthrough technology for lowering the biomanufacturing cost of biomanufacturing gene therapies
Eukarÿs and Genethon have announced a strategic partnership to reduce the cost of gene therapy drugs production. By combining Eukarÿs’ innovative disruptive C3P3 technology, which enhances unleashes mRNA synthesis in mammalian cells, with Genethon’s expertise in AAV vector production, the partnership aims to significantly increase production yields, leading to more affordable and accessible gene therapies. Eukarÿs’ C3P3 enzyme can multiply the production yields of all other biomedicines by a factor of 5 to 7. Without requiring any adaptation or investment in new equipment, nor any changes toin existing industrial processes, thus changing the game improving the efficiency of biomanufacturing in biomedicines manufacturing. This collaboration will help accelerate the development of cost-effective gene therapies for patients in need, and contribute to make them accessible to a wider part of the global population.

Access the full Press Release FR/ EN: